KR20250023547A - 히알루론산 유도체 의약 조성물 및 의약 조성물의 제조 방법 - Google Patents

히알루론산 유도체 의약 조성물 및 의약 조성물의 제조 방법 Download PDF

Info

Publication number
KR20250023547A
KR20250023547A KR1020257001420A KR20257001420A KR20250023547A KR 20250023547 A KR20250023547 A KR 20250023547A KR 1020257001420 A KR1020257001420 A KR 1020257001420A KR 20257001420 A KR20257001420 A KR 20257001420A KR 20250023547 A KR20250023547 A KR 20250023547A
Authority
KR
South Korea
Prior art keywords
hyaluronic acid
acid derivative
pharmaceutical composition
group
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257001420A
Other languages
English (en)
Korean (ko)
Inventor
고헤이 야부우치
다카시 나카이
Original Assignee
아사히 가세이 가부시키가이샤
아사히 가세이 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아사히 가세이 가부시키가이샤, 아사히 가세이 가부시키가이샤 filed Critical 아사히 가세이 가부시키가이샤
Publication of KR20250023547A publication Critical patent/KR20250023547A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Materials Engineering (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
KR1020257001420A 2022-07-20 2023-07-20 히알루론산 유도체 의약 조성물 및 의약 조성물의 제조 방법 Pending KR20250023547A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP2022115839 2022-07-20
JPJP-P-2022-115839 2022-07-20
JP2022115841 2022-07-20
JPJP-P-2022-115841 2022-07-20
JPJP-P-2022-151823 2022-09-22
JP2022151823 2022-09-22
PCT/JP2023/026679 WO2024019127A1 (ja) 2022-07-20 2023-07-20 ヒアルロン酸誘導体医薬組成物及び医薬組成物の製造方法

Publications (1)

Publication Number Publication Date
KR20250023547A true KR20250023547A (ko) 2025-02-18

Family

ID=89617852

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020257001420A Pending KR20250023547A (ko) 2022-07-20 2023-07-20 히알루론산 유도체 의약 조성물 및 의약 조성물의 제조 방법

Country Status (8)

Country Link
US (1) US20250360217A1 (https=)
EP (1) EP4559484A4 (https=)
JP (1) JPWO2024019127A1 (https=)
KR (1) KR20250023547A (https=)
CN (1) CN119584989A (https=)
CA (1) CA3262457A1 (https=)
TW (1) TWI868812B (https=)
WO (1) WO2024019127A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202600172A (zh) * 2024-04-11 2026-01-01 日商旭化成股份有限公司 載體組合物
CN120899772A (zh) * 2025-09-26 2025-11-07 中国热带农业科学院农产品加工研究所 一种抗血栓的微生物制剂及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010053140A1 (ja) 2008-11-05 2010-05-14 国立大学法人 東京医科歯科大学 ヒアルロン酸誘導体、およびその医薬組成物
JP2014534410A (ja) 2011-09-09 2014-12-18 アムジエン・インコーポレーテツド 食道および胃癌患者における抗肝細胞増殖因子（「ｈｇｆ」）抗体の有効性を予測するためのｃ−ｍｅｔタンパク質の使用
US20200237859A1 (en) 2019-01-25 2020-07-30 Newport Research, Inc. Aqueous suspensions of cyclosporin

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1142566B1 (fr) * 2000-04-07 2003-10-01 Laboratoire Medidom S.A. Formulations ophtalmiques à base de ciclosporine, d'acide hyaluronique et du polysorbate
US20050009836A1 (en) 2003-06-26 2005-01-13 Laskar Paul A. Ophthalmic composition containing quinolones and method of use
JP5468757B2 (ja) * 2007-09-04 2014-04-09 ロート製薬株式会社 線維芽細胞増殖促進能を有する組成物
PL2696687T3 (pl) 2011-04-12 2017-06-30 Novo Nordisk A/S Pochodne podwójnie acylowanej GLP-1
CN104888224B (zh) * 2015-03-25 2019-02-01 中山大学 一种两亲性多糖衍生物/泊洛沙姆温敏型原位水凝胶及其制备方法
ES3044918T3 (en) 2016-03-25 2025-11-27 The Univ Of Osaka Conjugate vaccine targeting disorder-causing in vivo protein
JP7734537B2 (ja) * 2020-09-07 2025-09-05 旭化成株式会社 点眼剤
JP7801899B2 (ja) 2021-01-28 2026-01-19 ケミプロ化成株式会社 新規な１，１０－フェナントロリン化合物を用いた有機エレクトロルミネッセンス素子、及び有機エレクトロルミネッセンス照明
JP7313602B2 (ja) 2021-01-28 2023-07-25 三菱マテリアル株式会社 炭素材料の製造方法、二酸化炭素の分解方法
JP2022151823A (ja) 2021-03-26 2022-10-07 関西ペイント株式会社 低光沢塗料組成物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010053140A1 (ja) 2008-11-05 2010-05-14 国立大学法人 東京医科歯科大学 ヒアルロン酸誘導体、およびその医薬組成物
JP2014534410A (ja) 2011-09-09 2014-12-18 アムジエン・インコーポレーテツド 食道および胃癌患者における抗肝細胞増殖因子（「ｈｇｆ」）抗体の有効性を予測するためのｃ−ｍｅｔタンパク質の使用
US20200237859A1 (en) 2019-01-25 2020-07-30 Newport Research, Inc. Aqueous suspensions of cyclosporin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Toxicology 216(2005) 106-121

Also Published As

Publication number Publication date
EP4559484A4 (en) 2025-11-26
US20250360217A1 (en) 2025-11-27
JPWO2024019127A1 (https=) 2024-01-25
EP4559484A1 (en) 2025-05-28
TW202412822A (zh) 2024-04-01
CA3262457A1 (en) 2025-06-12
WO2024019127A1 (ja) 2024-01-25
CN119584989A (zh) 2025-03-07
TWI868812B (zh) 2025-01-01

Similar Documents

Publication Publication Date Title
Guan et al. N-trimethyl chitosan nanoparticle-encapsulated lactosyl-norcantharidin for liver cancer therapy with high targeting efficacy
KR20250023547A (ko) 히알루론산 유도체 의약 조성물 및 의약 조성물의 제조 방법
CN102037058B (zh) 多西紫杉醇高分子衍生物、及其制造方法及其用途
KR20050104152A (ko) 경구용 약물의 흡수를 증진하는 약제학적 조성물
Yamada et al. Chitosan oligomers as potential and safe absorption enhancers for improving the pulmonary absorption of interferon-α in rats
KR20220020821A (ko) 이중 glp1/2 아고니스트의 약학적 비경구 조성물
US10328093B2 (en) Anthracycline formulations
JP7818130B2 (ja) ヒアルロン酸誘導体、医薬組成物、及び医薬組成物の製造方法
US10314880B2 (en) Composition comprising bortezomib
CN103961320A (zh) 一种免疫调节剂多肽缓释微球制剂及其制备方法
KR20170102061A (ko) 음이온-양이온성 환형다당류 조성물인 벤다무스틴
CN117599013A (zh) 纳米组合物及其制备方法和用途
CN1646172A (zh) 包含喜树碱衍生物的液体制剂以及冻干该制剂制得的药物组合物
US10213474B2 (en) Delivery of drugs
KR20190005884A (ko) 고분자화 약물 함유 약제학적 조성물
KR20090040299A (ko) 특별히 표적화된 국소 투여를 위한 주사용 약제학적 조성물
TWI859990B (zh) 玻尿酸衍生物醫藥品組合物及醫藥品組合物
CN104688677B (zh) 一种稳定的甘精胰岛素注射液及其制备方法
US20230233473A1 (en) Synergistic anti-viral pharmaceutical composition containing targeting nanoparticles
박주호 Design and therapeutic evaluation of heparin based bioconjugate for oral delivery and antiangiogenic therapy
EA029942B1 (ru) Стабильная фармацевтическая композиция на основе конъюгатов биологически активных белков с полиэтиленгликолем, содержащих азогруппу

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20250115

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination
PG1501 Laying open of application